Maravai LifeSciences Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRVI research report →
Range $8 – $11
Price Chart
About the company
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types.
- CEO
- Bernd Brust
- IPO
- 2020
- Employees
- 410
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on MRVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.98B
- P/E
- -16.14
- PEG
- -0.26
- P/S
- 18.26
- P/B
- 5.47
- EV/EBITDA
- -98.70
- Div Yield
- 0.00%
- Gross Margin
- 38.87%
- Op Margin
- -18.77%
- Net Margin
- -30.83%
- ROE
- -31.86%
- ROIC
- -6.99%
Latest fiscal year · YoY change
- Revenue
- $185.74M-28.3%
- Gross Profit
- $33.39M-69.2%
- Op Income
- $-6,738,000
- Net Income
- $-130,773,000+9.7%
- EPS
- $-0.91+13.3%
- OCF Growth
- -871.2%
- FCF Growth
- -218.7%
- 52W High
- $9.42
- 52W Low
- $2.80
- 50D MA
- $7.42
- 200D MA
- $5.51
- Beta
- 0.63
- RSI (14)
- 43
- Avg Volume
- 2.83M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Maravai posted solid Q3 growth led by mRNA and Cygnus, with margin expansion and a higher full-year outlook as management said the pipeline remains healthy.· November 4, 2026
- Revenue was $45.9 million, up 10% year over year, with TriLink up 12% and Cygnus up 8%.
- Adjusted gross margin expanded more than 1,700 basis points year over year to 57.7%, and adjusted EBITDA improved by $16.6 million to $5.8 million.
- mRNA was a standout: discovery mRNA grew 27% and GMP consumables grew 30%, while TriLink added more than 70 new discovery customers and 4 more customers moved from RUO to GMP.
- Management raised 2026 guidance to $212 million-$216 million of revenue and $40 million-$42 million of adjusted EBITDA.
- The company said GMP and CDMO remain lumpy quarter to quarter, but it sees strong visibility into the funnel and expects continued margin expansion.
Q3 revenue was $45.9 million, up 10% year over year. GAAP net loss before noncontrolling interest was $24 million versus $45.1 million a year ago; basic and diluted loss per share was $0.09 versus $0.18, and adjusted EPS was a loss of $0.03 versus a loss of $0.08. Adjusted gross margin expanded more than 1,700 basis points year over year to 57.7%, and adjusted EBITDA was $5.8 million, up $16.6 million year over year. TriLink revenue was $28.4 million, with mRNA revenue of $15.3 million up 28%, specialty chemistry $11 million down 4%, and CDMO $2 million up 8%; Cygnus revenue was $17.4 million and adjusted EBITDA was $12.5 million with 71% margins. Cash ended at $73 million and debt was $147 million. Management raised 2026 revenue guidance to $212 million-$216 million from $205 million-$215 million and raised full-year adjusted EBITDA guidance to $40 million-$42 million from $33 million-$35 million, while expecting adjusted gross margin expansion of greater than 1,600 basis points year over year.
Bernd Brust framed the quarter as evidence that Maravai’s restructuring and operating model are starting to show through in both growth and profitability. He emphasized the strategic importance of mRNA, pointing to strong demand in discovery, GMP consumables, and a broad pipeline across cancer vaccines, rare disease, gene editing, and infectious disease. He was upbeat but measured, repeatedly noting that not every program will succeed and that GMP/CDMO revenue can be timing-dependent.
Rajesh J. Asorpota focused on mix-driven profitability, saying adjusted EBITDA improved because of stronger revenue, a favorable mix toward high-margin GMP and mRNA discovery, and OpEx discipline. He highlighted $73 million of cash, $147 million of debt, $12.2 million of depreciation and amortization, $3.4 million of net interest expense, and $10.1 million of stock-based compensation. He also said the company expects further gross margin expansion and that the raised guidance reflects visibility into Q4, while still acknowledging quarterly variability in GMP and CDMO orders.
Analysts pressed management on 2027 growth, the durability of mRNA discovery demand, and whether recent funding improvements are helping smaller biotech customers. Management said it is too early to give formal 2027 guidance but said discovery looks healthy across base and advanced programs and that the GMP funnel is strong. On ModTail, management said adoption has exceeded 180 customers and GMP material will be available, but it does not expect massive GMP dollars in 2027. On China, management said TriLink is starting from near zero while Cygnus is already seeing good growth there, and that the new China patent and sales presence should help future expansion.
The call showed accelerating mRNA momentum, with discovery up 27% and GMP consumables up 30%, plus more than 70 new discovery customers and 10 RUO-to-GMP conversions year to date. Management said the pipeline is healthy, conversion opportunities are building, and the company has room for further margin expansion as the reset cost base scales.
Management repeatedly warned that GMP, CDMO, and some large orders are lumpy, so quarter-to-quarter growth can swing based on timing rather than demand. The company also said some mRNA cancer vaccine programs recently disappointed, not every clinical program will succeed, and meaningful GMP revenue from newer offerings like ModTail may be limited in 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 71.4%
- Shares Outstanding
- 149.25M
- Float Shares
- 106.63M
of shares held by institutions
187 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MRVI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gtcr LLC | 20.15M | 0 |
| Blackrock, Inc. | 10.56M | ▲ 591.37K |
| Braidwell LP | 8.70M | ▼ 1.54M |
| Vanguard Group Inc | 7.17M | ▲ 41.03K |
| 12 West Capital Management LP | 7.06M | ▼ 200.00K |
| Fmr LLC | 6.90M | ▲ 6.87M |
| Millennium Management LLC | 6.51M | ▲ 4.86M |
| Vanguard Capital Management LLC | 5.25M | ▼ 31.89K |
| Ophir Asset Management Pty Ltd | 4.83M | ▲ 4.83M |
| Renaissance Technologies LLC | 3.99M | ▼ 618.60K |
| Nuveen, LLC | 3.49M | ▲ 633.87K |
| First Eagle Investment Management, LLC | 3.28M | ▼ 388.96K |
Held by 227 ETFs
Biggest fund positions in MRVI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Brust Bernd | other | 29,250 |
| Oct 30, 26 | Asarpota Rajesh | other | 5,466 |
| Oct 8, 26 | Brust Bernd | other | 29,250 |
| Sep 30, 26 | Asarpota Rajesh | other | 5,465 |
| Sep 8, 26 | Brust Bernd | other | 29,250 |
| Aug 31, 26 | Asarpota Rajesh | other | 5,465 |
| Aug 10, 26 | Brust Bernd | other | 29,250 |
| Jul 30, 26 | Asarpota Rajesh | other | 5,465 |
| Jul 8, 26 | Brust Bernd | other | 29,250 |
| Jun 30, 26 | Asarpota Rajesh | other | 65,584 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MRVI coverage
Recent articles, reports, and earnings notes.
No research on MRVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MRVI report →Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 4
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
businesswire.com · Oct 14
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Has Average Price Target of $6.83
defenseworld.net · Oct 5
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
businesswire.com · Sep 29
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel
seekingalpha.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.